CEO Dr Mark Payton joined Proactive’s Stephen Gunnion with more on the company’s strong full-year 2024 performance. Dr Payton also highlighted Mercia’s strong financial performance, including growth in revenue, EBITDA, and its proposed final dividend, and shared ambitious goals for the next three years, including doubling EBITDA and raising assets under management to £3 billion.
Mercia Preliminary Results FY24 presentation presented by Dr Mark Payton and Martin Glanfield.
Mercia Asset Management PLC, is pleased to announce its preliminary results for the year ended 31 March 2024. Set against another year of subdued inflows by the asset management sector, Mercia achieved record fund inflows of c.£562million during the year and increased revenues, EBITDA, adjusted operating profit, dividends and cash. 31 March 2024 31 March
Powering growth Overview The year to 31 March 2024 was characterised by market volatility, high inflation and high interest rates driving up the costs of doing business, alongside geopolitical uncertainty and a thankfully short-lived recession. It is therefore pleasing to have come through these universal headwinds with record organic growth in our assets under management,
Strong progress Overall financial performance Notwithstanding the inflationary challenges affecting the UK economy in general and more specifically the financial services sector during Mercia’s financial year to 31 March 2024, the Group was able to increase its EBITDA compared with the prior year. This was due in part to the continuing positive performance of FDC.
Powering forward Assessing market dynamics In our November 2023 interim report, I discussed prevailing market conditions and importantly, Mercia’s strategic response. I noted: “…we have advised our investees to remain focused on their strategies, bolstered by adequate cash reserves and our disciplined support, to concentrate on the controllable elements and run their businesses efficiently.” This
Generative AI, powered by Microsoft and OpenAI, offers exciting possibilities for your organisation. In an exclusive session for Mercia portfolio businesses, we’ll explore how this technology can enhance your tech solutions.
UK-based Contract Research Organisation (CRO) Gentronix – a leading specialist toxicology firm based at Alderley Park – has been awarded the King’s Award for Enterprise after achieving a triple-figure revenue growth following rapid expansion in international markets. Gentronix recorded total growth of 239% in overseas earnings over the past three years, with the percentage of
Earlier this year, we participated in a £7.5m seed round into IsomAb, a UK-based biotechnology company developing a novel treatment for a common cardiovascular condition. The links between heart health and lifestyle are well known but deaths from cardiovascular diseases continue to rise. In fact, one such disease, atherosclerosis, has now surpassed communicable diseases to
The transition towards biomanufacturing, and the move away from traditional, energy-intensive processes in industry is creating unprecedented opportunities for start-ups. Understanding the investor’s perspective in this space can help founders prepare more effectively for their fundraise. Below is a snippet of some of the most critical aspects we and other investors look for at the